Syndecan-2, a transmembrane heparansulfate proteoglycan, is a critical mediator in the tumorigenesis of colon carcinoma cells. We explored the function of syndecan-2 in melanoma, one of the most invasive types of cancers and found that the expression of this protein was elevated in tissue samples from both nevus and malignant human melanomas, but not in melanocytes of the normal human skin tissues. Similarly, elevated syndecan-2 expression was observed in various melanoma cell lines. Overexpression of syndecan-2 enhanced migration and invasion of melanoma cells, while the opposite was observed when syndecan-2 levels were knocked-down using small inhibitory RNAs. Syndecan-2 expression was enhanced by fibroblasts growth factor-2, which is known to stimulate melanoma cell migration; however, α-melanocyte stimulating hormone (α-MSH) decreased syndecan-2 expression and melanoma cell migration and invasion in a melanin synthesis-independent manner. Furthermore, syndecan-2 overexpression rescued the migration defects induced by α-MSH treatment. Together, these data strongly suggest that syndecan-2 plays a crucial role in the migratory potential of melanoma cells.
Syndecan-2, a transmembrane heparansulfate proteoglycan, is a critical mediator in the tumorigenesis of colon carcinoma cells. We explored the function of syndecan-2 in melanoma, one of the most invasive types of cancers and found that the expression of this protein was elevated in tissue samples from both nevus and malignant human melanomas, but not in melanocytes of the normal human skin tissues. Similarly, elevated syndecan-2 expression was observed in various melanoma cell lines. Overexpression of syndecan-2 enhanced migration and invasion of melanoma cells, while the opposite was observed when syndecan-2 levels were knocked-down using small inhibitory RNAs. Syndecan-2 expression was enhanced by fibroblasts growth factor-2, which is known to stimulate melanoma cell migration; however, α-melanocyte stimulating hormone (α-MSH) decreased syndecan-2 expression and melanoma cell migration and invasion in a melanin synthesis-independent manner. Furthermore, syndecan-2 overexpression rescued the migration defects induced by α-MSH treatment. Together, these data strongly suggest that syndecan-2 plays a crucial role in the migratory potential of melanoma cells.
The syndecans, a family of four transmembrane cell surface heparan sulfate proteoglycans, mainly serving as a coreceptor, regulate the adhesion-dependent signal transduction of a variety of cell types, including cancer cells (1, 2) . Cell adhesion receptors or co-receptors play a critical role in the neoplastic transformation of normal cells by regulating the induction of cancerspecific cellular behavior and morphology. Thus, cancer cells likely express and utilize a distinct set of syndecans in the regulation of cancer cell growth.
Several reports have linked altered syndecan expression to various elements of cancer cell growth. Loss of syndecan-1 correlates with shorter survival times in patients with squamous cell carcinoma of the head, neck and lung (3), as well as multiple myeloma (4) ; loss of syndecan-1 is also associated with an elevated potential for metastasis in patients with hepatocellular and colorectal carcinomas (5, 6) . Previous studies have shown that syndecan-1 regulates tumor activity in pancreatic (7) , gastric (8) and breast carcinomas (9) . Syndecan-1 may thus play multiple roles in tumorigenic activity and perform various tissue-and/or tumor stage-specific functions (10) . Syndecan-4 expression is reduced in colon carcinoma cells (11, 12) and appears to correlate with increased tumorigenic activity [e.g., cell migration and invasion (13) ], implying that syndecan-4 functions as a tumor suppressor.
Syndecan-2 is also known to play a crucial role in the regulation of cancer activity. Increased levels of syndecan-2 confer an invasive phenotype in lung (14) and colon cancer cells (15) . Reduction in syndecan-2 expression induces cells to switch from the transformed phenotype to flattened monolayers (8) , and reduces tumorigenic activity in colon adenocarcinoma and fibrosarcoma cells (8, 16) . In addition, syndecan-2 is highly expressed in the microvasculature of mouse gliomas and has been shown to regulate angiogenesis in microvascular endothelial cells (17) . On the other hand, an inverse correlation between syndecan-2 expression and metastatic potential has been found in Lewis lung carcinoma cell lines (6) . Therefore, changes in syndecan-2 expression may directly or indirectly regulate cancer growth.
Melanoma is a most aggressive malignant tumor of melanocytes. Although found predominantly in the skin, primary melanoma are also known to occur in the bowel and eye (18) . Malignant melanoma is notoriously one of the most difficult cancers to treat (19) . Therefore, identifying and understanding molecules that regulate the aggressive melanoma phenotype is essential for predicting the likelihood of metastasis. Interestingly, previous studies have shown that melanoma cells acquire the ability to recognize components of the extracellular matrix (ECM) via the ectopic expression of different ECM receptors during invasion of the basement membrane (20) . Indeed, invadopodia, the dynamic organelle-like structure that form actin-rich protrusions with ECM proteolytic activity, adhere to and digest collagens, laminins and fibronectin (21) . The adhesive properties of invadopodia are primarily attributed to integrins, a large family of heterodimeric transmembrane receptors composed of α and β subunit s (22) . For example, β 1 integrins localize within the invadopodia of melanoma cells (23) , and the α 5 β 1 integrins are enriched peripherally in invadopodia, where they stabilize invadopodia protrusion (24) . Ectopic stimulation of α 6 β 1 integrin with laminin peptides or with β 1 or α 6 integrin stimulatory antibodies increases invadopodia activity and melanoma invasiveness (23) . The invasive behavior of melanoma cells can be attributed to increased cell motility caused by changes in cytoskeletal organization and altered contacts with the ECM. Thus, cell adhesion receptors may play a crucial role in the acquisition of highly migratory behavior.
Syndecan-2 acts as a key regulator of cancer cells, suggesting that syndecan-2 may contribute to the aggressive phenotype and metastatic potential of melanoma. Here, we report that syndecan-2 plays a pivotal role in the migratory activity of melanoma cells. . A portion of rat syndecan-2 cDNA representing the extracellular domain (S2E) was amplified by polymerase chain reaction and cloned upstream of human immunoglobulin heavy chain constant region (Fc) constructed in both pAGCF and pAGPCF2; the former utilized the natural leader sequence whereas the latter used the plasminogen activator inhibitor-1 (PAI-1) leader peptide. The Fc-fusion constructs were transfected into human embryonic kidney 293 (HEK293) cells. DMEM serum-free media was used to collect rat syndecan-2-Fc fusion protein from confluent cells for 2 days. The media was harvested and spun down to remove cells, and the pH was adjusted to 8.0 with 1 M Tris. The media was then filtered with a 0.4-μm filter and loaded onto a Protein-A column, eluted with a 100 mM glycine, pH 3.0 and was immediately neutralized with one-tenth volume of 1 M Tris pH 8.0. Both constructs yielded similar amounts of rat syndecan-2-Fc. Balb/c mice were repeatedly immunized with S2E-Fc fusion protein until the polyclonal sera from the immunized mice exhibited strong immune responses. Splenocytes were isolated from the mice and fused to mouse myeloma Sp2/0. Screening and single cell cloning were conformed to the established standard protocol. Ascites were prepared from the immunocompromised Balb/c mice. Immunoglobulin fractions were prepared through Protein G.. One stable hybridoma clone (#197) secreting mAbs against syndecan-2 were obtained (Fig. 1 harvested, washed twice with cold PBS and then incubated with syndecan-2 cDNA on ice for 20 minutes. Transfections were carried out by electroporation using 0.2 kV, 1 pulse time, and 15 seconds of length). The G148 resistant clones were selected in 3 weeks. Syndecan-2 expression was assessed by RT-PCR using syndecan-2 specific primer.
EXPERIMENTAL PROCEDURES

Reagents and antibodies-Monoclonal
Immunoprecipitation and immunoblotting-
The cultures were washed twice with PBS and the cells were lysed in RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 10 mM NaF, 2 mM Na 3 VO 4 ) containing a protease inhibitor cocktail (1 μg/ml aprotinin, 1 μg/ml antipain, 5 μg/ml leupeptin, 1 μg/ml pepstatin A, 20 μg/ml phenylmethylsulfonyl fluoride). The lysates were clarified by centrifugation at 13,000 rpm for 15 minutes at 4 , denatured with ℃ SDS sample buffer, boiled, and analyzed by SDS-PAGE. For immunoprecipitations, each sample containing 200 to 1,000 μg of total protein was incubated with the relevant antibody for 2 hours at 4 followed by ℃ Migration assay-Gelatin (10 μg/ml) was added to each well of a Transwell plate (Costar; 8-µm pore size), and then the membranes were allowed to dry at 25 °C for 1 hour. The Transwell plates were assembled in a 24-well plate, and the lower chambers were filled with FGF-2 (100 ng/ml) in fresh media. Cells (5 X 10 4 ) were added to each upper chamber, and the plates were incubated at 37 °C in 5% CO 2 for 12 hours. The cells that had migrated to the lower surface of the filters were stained with 0.6% hematoxylin and 0.5% eosin and counted. For in vitro invasion assays, 24-well Transwell plates (Costar; 8-µm pore size) were coated with gelatin (10 μg/ml) on the lower side of the membrane and with Matrigel (30 µg/µl) on the upper side. Tumor Metastasis-For in vivo experimental pulmonary metastasis assays, B16F10 melanoma cells (1 X 10 5 cells/mouse) were injected into a tail vein of C57BL/6 mice (n=10) on day 0. On day 13, lungs were excised and metastatic nodules were photographed. Biopsy-Two millimeter punch biopsies were obtained from patients who gave their informed consents in accordance with the policy of The Catholic Research Medical Institutional Review Board. The punch biopsies were taken from the malignant lesions and normal dermis of patients who visited the out-patient clinic. Biopsies were immediately frozen in the liquid nitrogen and kept at -70 o C until used for further analysis. Immunohistochemistry-Five sets of biopsies from patients were fixed in 10% neutralized buffered formalin for 24 hours, embedded in paraffin, sectioned and deparaffinized for staining. The sections were stained with hematoxylin and eosin. For immunostaining, the sections were rinsed and endogenous peroxidase activity was blocked with 3% hydrogen peroxide and 10% methanol in PBS, followed by preincubation in PBS containing 0.2% Triton X-100 (PBS-T) and 3% bovine serum albumin (BSA) for 2 hours. The sections were then incubated for 16 hours in PBS-T containing either anti-SDC2 antibody ( 1: 1000) or anti-melanosome HMB-45 antibody (1:50). Following wash with PBS, they were then rinsed and incubated with biotinylated secondary antibody (1:1,000, Dako, Denmark) in PBS-T containing 3% BSA, for 60 minutes at room temperature. The sections were subsequently rinsed and incubated with peroxidase-labeled streptavidin (Dako, Denmark) for 60 minutes, followed by reaction with diaminobenzidine (0.5 mg/ml) and hydrogen peroxide. After rinsing, the sections were mounted, dehydrated, and covered with coverslips. All images were acquired with a Carl Zeiss Axioskop2. Wound-healing assay-Melanoma cells were plated 60-mm tissue culture plates and incubated overnight. After one streak was made in the middle of the monolayer using a sterile pipette tip, the cells were washed twice with PBS and cultured in fresh media. Pictures of the wound distance were taken at various time points.
Measurement of melanin content-Melanin
by guest on July 18, 2017 http://www.jbc.org/ Downloaded from contents were measured as reported by Kazuomi et al (26) . Briefly, cells were treated with either 1.0 μM α-MSH or 200 μM Kojic acid in DMEM containing 10 % heat inactivated FBS for 48 hours and then detached by incubation with trypsin/EDTA. After pelleting, cells were resuspended in DMEM for cell counting, or solubilized into boiling 2 M NaOH for 20 minutes. After cooling to room temperature, the absorbance of the solution was measured at 405 nm for melanin content determination.
Cell proliferation assay-Cell proliferation was measured by a colorimetric assay using MTT as described (3) .
RESULTS
Syndecan-2 is upregulated in melanoma cells-
To investigate the role of syndecan-2 in the development of human skin melanoma, the expression of syndecan-2 was compared in tissues obtained from cutaneous malignancies and normal skin. Immunohistochemical studies revealed the absence of syndecan-2 expression in normal skin ( Fig. 2A, b, c) . On the other hand, we found that there was increased syndecan-2 expression in intradermal nevus ( Fig. 2A, g,  h) . To our interest, syndecan-2 expression was significantly increased in malignant melanomas ( Fig. 2A, l, m) stained positively with melanoma-marker, HMB-45 in the adjacent slide ( Fig. 2A, e, i, j, n, o) , while pre-immune serum showed no staining except for the melanin granules in the malignant melanoma (Fig 2A, d) . Consistent with this observation, elevated cell surface expression of syndecan-2 was observed in human melanoma cell lines (Fig. 2B) . These data suggest that syndecan-2 expression is increased in human melanoma cells.
Syndecan-2 regulates melanoma cell
migration-Syndecan-2 is known to play critical role as an adhesion receptor during cell migration. To more directly assess the role of syndecan-2 in the regulation of tumorigenic activity, we examined the effects of syndecan-2 expression on melanoma cell migration. Human melanoma A375 cells were transfected with syndecan-2 cDNA (sdc2) and transwell migration assay was performed (Fig. 3A) . After transfection with sdc2, both cell migration and invasion were significantly higher in A375 cells than in vector-transfected cells (i.e., vec). In contrast, cell migration/invasion was decreased when syndecan-2 expression was suppressed by small interfering RNAs (siRNAs) (Fig. 3B) . Consistent with the human melanoma cells, elevated cell surface expression of syndecan-2 was also observed in mouse melanoma cell lines (Fig. 4) . Interestingly, B16F10 cells expressing higher levels of syndecan-2 migrated faster than B16 cells (Fig. 4A) . Syndecan-2 overexpression enhanced the migration of mouse melanoma B16 cells, based on transwell migration (Fig. 4B ) and wound healing assays (Fig. 4C) , while cell migration decreased when syndecan-2 expression was suppressed by siRNAs (Fig.  4D) . Similar results were observed using B16F10 cells (data not shown). Consistently, knockdown of syndecan-2 expression by siRNA reduced metastatic potential of B16F10 melanoma cells in mice (Fig. 4E) . These findings strongly suggest that syndecan-2 regulates cell migration in melanoma cells. Focal adhesion kinase (FAK) is known to play a pivotal role in cancer cell migration (27, 28) . Accordingly, we found that total cellular tyrosine phosphorylation was enhanced in sdc2-overexpressing B16 melanoma cells. In particular, tyrosine phosphorylation of seven different by guest on July 18, 2017
http://www.jbc.org/ Downloaded from polypeptides (i.e., p200, p125, p90, p64, p54, p44, and p42) was higher in cells transfected with sdc2 than in cells transfected with the control vector (Fig. 5A, left panel) . Since enhanced tyrosyl phosphorylation mediated by FAK often happens in response to stimulation cell migration (29) , the same membrane was striped and reprobed with antibodies against FAK or paxillin, a well known substrate of FAK (30) . FAK was detected on the position of p125 and paxillin on the position of p64 (Fig. 5A, right panel) , suggesting involvement of FAK tyrosine phosphorylation. Indeed, sdc2 expression increased autophosphorylation at tyrosine 397 (i.e., Y397), phosphorylation of FAK at tyrosine 861 (i.g., Y861; known to regulate cell transformation) (Fig. 5B) , and tyrosyl phosphorylation of paxillin (Fig. 5C ). These data indicate that syndecan-2-induced migration activity is intimately associated with the activation of FAK-mediated signaling.
Syndecan-2 expression correlates with melanoma cell migration-
The previous study demonstrated the stimulatory effects of FGF-2 on melanoma cell migration (31) . In parallel with increased cell migration, FGF-2 caused increased cell surface expression of syndecan-2 ( Fig. 6A) , suggesting that syndecan-2 expression correlates with FGF-2-enhanced cell migration. Bovine pituitary extract (BPE) is routinely used as a mitogenic supplement in growth media for human melanocytes (32) . In contrast to FGF-2 treatment, BPE treatment reduced cell surface expression of syndecan-2 and melanoma cell migration (Fig. 6B) , supporting the idea that syndecan-2 expression correlates with melanoma cell migration. (Fig. 7F) . Furthermore, syndecan-2 overexpression rescued the migration defects induced by α-MSH treatment (Fig. 8) . Collectively, these results suggest that α-MSH inhibits melanoma cell migration through reduced expression of syndecan-2 and support the idea that syndecan-2 expression plays a crucial role in melanoma cell migration.
α-MSH inhibits melanoma cell migration through reduced expression of syndecan-2-
Syndecan-2-mediated cell migration occurs independently of melanin synthesis-
The production of melanin pigments is stimulated by α-MSH in the skin, hair and eye (34) . α-MSH stimulates upregulation of intracellular cAMP and sequential activation of various pigmentation enzymes (e.g., tyrosinase, which catalyzes a rate-limiting step in melanin synthesis) (35) . Therefore, we investigated whether melanin synthesis plays a role in the syndecan-2-mediated cell migration of melanoma cells. Consistent with previous findings (36), α-MSH enhanced the melanin content of melanoma cells (i.e., by approximately 121%), whereas melanin production was reduced by treatment with the tyrosinase inhibitor, kojic acid (i.e., by approximately 76%) (Fig. 9A ) (26) . In contrast, syndecan-2 expression decreased in response to treatment with α-MSH, but did not change in response to kojic acid (Figs. 9B) . Accordingly, α-MSHmediated reductions in cell migration corresponded with reduced syndecan-2 expression, whereas inhibition of tyrosinase activity did not influence melanoma cells migration (Fig. 9C) . Therefore, it appears that α-MSH regulates syndecan-2-mediated cell migration independent of the melanin biosynthesis pathway.
DISCUSSION
Cell migration is a critical step in tumor invasion and metastasis, two major causes of death among cancer patients. We previously reported that elevated syndecan-2 expression is crucial for tumorigenic activity in colon carcinoma and fibrosarcoma cells (3, 29) . Here, we provide further evidence for the tumorigenic activity of syndecan-2 using melanoma, one of the most highly invasive types of cancers. Consistent with our previous findings in colon carcinoma and fibrosarcoma cells, we identified syndecan-2 expression in tissue samples from both nevus and malignant human melanomas, but not in normal melanocytes (Fig. 2A) . Similarly, syndecan-2 expression was elevated in all melanoma cell lines tested (Fig. 2B) . Increased syndecan-2 expression correlates with increased melanoma cell migration, while the opposite effects were observed when syndecan-2 expression was suppressed using siRNAs (Figs. 3 & 4) . Therefore, syndecan-2 appears to act as a general protumorigenic receptor in cancer cells.
Although melanoma cell migration is associated with syndecan-2 expression, little is known about the mechanism of syndecan-2-mediated regulation of melanoma cell migration. Our results indicate that enhanced FAK signaling plays a role in the regulation of syndecan-2-mediated cell migration. Overexpression of syndecan-2 increased phosphorylation of FAK and its substrate, paxillin (Fig. 5) . Boukerche et al. recently reported that the invasion and metastatic spread of melanoma cells is regulated by elevated syntenin expression and enhanced via FAK-and p38-induced activation of NF-κB (37). Syntenin is an adaptor molecule that binds to the cytoplasmic domain of syndecans; thus, it also may play an important role in the syndecan-2-mediated migration of melanoma cells.
Melanocytes and melanoma cells may differ with regards to the cell surface expression of syndecan-2 that appears to play a critical role in the migration of melanoma cells. Syndecan-1 is required for the induction of mammary tumor formation by the proto-oncogene, Wnt-1, which mediates expression of oncogenes such as Tcf-1, LEF1, Axin-2, and matrix metalloproteinase 7 (38). However, we found that Wnt 3a did not influence syndecan-2 expression (data not shown), implying that the Wnt/β-catenin pathway is not involved in the regulation of syndecan-2-mediated cell migration.
Interestingly, syndecan-2 expression was regulated by α-MSH, a pituitary-derived peptide that stimulates melanin production. Previous studies have found that increased α-MSH levels are associated with melanoma progression (34, 39) . However, α-MSH is also known to reduce the abilities of human cutaneous and ocular melanoma cells to invade the ECM (40), and is a potent inhibitor of invasion by highly invasive B16-BL6 murine melanoma cells (39,41). Our findings suggest that α-MSH negatively regulate melanoma cell migration via reduced syndecan-2 expression (Fig. 7) . Indeed, FGF-2 upregulated syndecan-2 expression and increased melanoma cell migration (Fig. 6) , while BPE or α-MSH downregulated syndecan-2 expression and reduced melanoma cell migration (Figs. 6-8) . Although the exact role for α-MSH in melanoma cell migration remains unclear, our findings suggest that regulation syndecan-2 expression by α-MSH plays a crucial role in the migration of melanoma cells. Recent clinical studies have shown that a potent synthetic analogue of α-MSH, NDP-MSH, significantly increases the eumelanin content of human skin (42). Interestingly, α-MSH-mediated syndecan-2 expression occurs independently of melanin synthesis (Fig. 9) . Therefore, α-MSH may play independent roles in the regulation of syndecan-2 expression, in cell migration and in melanin biosynthesis pathway. In addition, it has been known that α-MSH suppresses melanoma cell migration induced by the inflammatory cytokine tumor necrosis factor α (TNF-α) (43). It has been also known that α-MSH inhibits the production of MMP-2 and MMP-9 and invasion of Matrigel by B16 melanoma cells (44). Therefore, we can not exclude the possibility that some other factors, unrelated to reduced syndecan-2 expression, could contribute to some extent to reduced cell migration via α-MSH.
In summary, syndecan-2, a cell surface heparansulfate proteoglycan, plays a critical role in regulating the migratory potential of melanoma cells. In addition, α-MSH negatively regulates the expression of syndecan-2 independently of the melanin biosynthesis pathway and reduces concomitant cell migration. As the treatment of melanoma remains extremely challenging, our evidence regarding the role of syndecan-2 in melanoma cell migration merits further investigation. These findings may provide clues as to the metastatic potential of the cancer and may pave the way for the development of novel therapies to reduce the metastasis of melanoma cells. The abbreviations used are: α-MSH, alpha-melanocyte stimulating hormone; FGF-2, fibroblast growth factor-2; CD, conditioned media; DMEM, Dulbecco's modified Eagle's medium; ECM, extracellular matrix; FAK, focal adhesion kinase; FBS, fetal bovine serum; SFM, serum-free medium were loaded to migrate on Transwell plates as described in Fig. 3 (bottom panel) . B, B16 cells were transfected with sdc2 cDNA. Total RNA was extracted, and expression of syndecan-2 was analyzed by reverse transcription-PCR. GAPDH mRNA was used as the loading control (top panel). Cells were incubated with an anti-syndecan-2 antibody, and the cell surface expression levels of syndecan-2 were analyzed by flow cytometry. IgG was used as a control (middle panel). Transwell migration assays were done with B16 cells transfected with 2 μg of the indicated cDNA as described in Fig. 3 (bottom panel) . C, B16 cells were transfected with sdc2 cDNA and 24 hours later, wound-healing assays were performed. One streak was made in the middle of the monolayer using a sterile pipette tip and pictures of the wound distance were taken at each time point. D, B16 cells were transfected with syndecan-2 siRNA. Cell surface expression levels of syndecan-2 were analyzed by flow cytometry. IgG was used as a control (top panel). Cells (5 X 10 4 ) were allowed to migrate on Transwell plates as described in Fig. 3 (bottom panel). E, B16F10 cells were transfected with syndecan-2 siRNA. Metastasis assay was performed as detailed under EXPERIMENTAL PROCEDURES. Two independent experiments were performed and each experiment conducted using three mice per group. Two representative photographs of both front and back side of each lung are shown. Columns, average of three independent experiments. * p<0.01, ** p<0.05 versus control. allowed to migrate on Transwell plates as described in Fig. 3 (bottom panel) . Columns, average of three independent experiments. * p<0.01 versus control. Fig. 7 . α-MSH inhibits expression of syndecan-2 paralleled with reduced cell migration. A, B16 cells were treated with α-MSH (1.0 μM) for 24 hours. Total RNA was extracted, and expression of syndecan-2 was analyzed by reverse transcription-PCR. β-actin mRNA was used as the loading control. B, B16 cells were treated with either FGF-2 (300 ng/ml) or α-MSH (1.0 μM). After 24 hours, total cell lysates were analyzed by slot blotting. C, B16 cells treated with the indicated amount of α-MSH (μM) for 24 hours were incubated with anti-syndecan-2 antibody, and the protein expression level was analyzed by flow cytometry. IgG was used as the negative control. D, B16 cells (5 X 10 4 ) pretreated with either FGF-2 (300 ng/ml) or α-MSH (0.5 μM, 1.0 μM) for 24 hours were allowed to migrate on Transwell plates as described in Fig. 3 . Columns, average of three independent experiments. E, B16 cells were pretreated with α-MSH (1.0 μM) for 24 hours. Transwell cell migration or invasion assay was performed as described in Fig. 3 . F, B16 cells were treated with either FGF-2 (300 ng/ml) or α-MSH (1.0 μM), and then MTT assays were performed. Columns, average of three independent experiments. * p<0.01, ** p<0.05 versus control. Fig. 8 . α-MSH inhibits melanoma cell migration through reduced expression of syndecan-2. B16 cells transfected with either the empty vector or sdc2 cDNA were treated with α-MSH (1.0 μM) for 24 hours. Syndecan-2 expression levels (A) and cell migration (B) were analyzed as described in Fig. 3 . Columns, average of three independent experiments. * p<0.01 versus control. Fig. 9 . Syndecan-2-mediated cell migration is independent of melanin synthesis. A, After B16F10 cells were treated with either α-MSH (1.0 μM) or kojic acid (200 μM) for 48 hours, the melanin content of the cells was measured as described under EXPERIMENTAL PROCEDURES. Cell surface expression of syndecan-2 (B) and cell migration activity (C) were analyzed as described in Fig. 3 . Columns, average of three independent experiments. * p<0.05, ** p<0.01 versus control. 
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